Literature DB >> 6208313

Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies.

J J Schlesinger, E E Walsh, M W Brandriss.   

Abstract

Sixteen monoclonal antibodies that reacted with the envelope glycoprotein (E) of 17D vaccine strain yellow fever virus (17D YF), including two antibodies produced against dengue 2 virus, were used in a solid phase competitive binding assay (CBA) to define spatial relationships among antigenic determinants on 17D YF E. The antibodies showed YF strain, type or flavivirus group specificities and nine epitopes were identified on 17D YF E by patterns of neutralization, haemagglutination inhibition and competition of antibody binding. Epitopes defined by neutralizing antibodies with strain and type specificities appeared spatially distant but competition between type-specific neutralizing antibodies and some non-neutralizing antibodies against type and group determinants suggested close proximity among epitopes in these regions. Despite competition between some neutralizing and non-neutralizing monoclonal antibodies in CBA, plaque assays revealed no interference with neutralization by non-neutralizing antibody.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208313     DOI: 10.1099/0022-1317-65-10-1637

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  9 in total

1.  Identification of envelope protein epitopes that are important in the attenuation process of wild-type yellow fever virus.

Authors:  B K Sil; L M Dunster; T N Ledger; M R Wills; P D Minor; A D Barrett
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

2.  Comparative immunochemical and biological analysis of African and South American yellow fever viruses.

Authors:  V Deubel; J J Schlesinger; J P Digoutte; M Girard
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

3.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

Review 4.  The structural immunology of antibody protection against West Nile virus.

Authors:  Michael S Diamond; Theodore C Pierson; Daved H Fremont
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

5.  Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimens.

Authors:  T P Monath; L J Hill; N V Brown; C B Cropp; J J Schlesinger; J F Saluzzo; J R Wands
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

6.  Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii.

Authors:  Cristina T Stoyanov; Silvia B Boscardin; Stephanie Deroubaix; Giovanna Barba-Spaeth; David Franco; Ruth S Nussenzweig; Michel Nussenzweig; Charles M Rice
Journal:  Vaccine       Date:  2010-05-06       Impact factor: 3.641

7.  Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes.

Authors:  Giovanna Barba-Spaeth; Randy S Longman; Matthew L Albert; Charles M Rice
Journal:  J Exp Med       Date:  2005-10-31       Impact factor: 14.307

8.  Epitopes on the peplomer protein of infectious bronchitis virus strain M41 as defined by monoclonal antibodies.

Authors:  H G Niesters; N M Bleumink-Pluym; A D Osterhaus; M C Horzinek; B A van der Zeijst
Journal:  Virology       Date:  1987-12       Impact factor: 3.616

9.  Impact of yellow fever virus envelope protein on wild-type and vaccine epitopes and tissue tropism.

Authors:  Emily H Davis; Binbin Wang; Mellodee White; Yan-Jang S Huang; Vanessa V Sarathy; Tian Wang; Nigel Bourne; Stephen Higgs; Alan D T Barrett
Journal:  NPJ Vaccines       Date:  2022-03-23       Impact factor: 9.399

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.